
NEW YORK SOCIETY FOR GASTROENTEROLOGY & ENDOSCOPY

48th Annual NEW YORK COURSE December 12-13, 2024 • New York, NY



Celiac Mimickers: A Sheep in Wolf's Clothing





Amy S. Oxentenko, MD FACP, FACG Professor of Medicine, Mayo Clinic College of Medicine & Science Vice Dean of Practice, Mayo Clinic Consultant, Division of Gastroenterology/Hepatology

Oxentenko.amy@mayo.edu



DISCLOSURES

None... other than I consume gluten!




New York Society for Gastroenterology and Endoscopy

Objectives

Detail	Identify	Outline
Detail the entities that can mimic celiac disease either clinically or histologically	Identify the clinical and/or histologic differences to be able to distinguish between the differing disorders	Outline an approach to the patient with serologically- negative enteropathy

A8th Annual New York Course

Normal Small Bowel




Goblet cell

Lymphocyte


Small bowel mucosa

Enterocyte

Celiac Disease




- Flattened villi (partial/total)
- Crypt hyperplasia



- Increased IELs
- Chronic inflammatory cell infiltrate in lamina propria


Early Histologic Mimickers

IELs, no atrophy (Marsh 1 and 2)




Intraepithelial Lymphocytes (IELs):What is "Abnormal"?

 $2005: \ge 25$ IELs/100 epithelial cells (prior 40)



Excluding known CD, only 6.8% dx with CD



Shmidt E, Smyrk TC, Boswell CL, Enders FT, Oxentenko AS, GIE 2014;80:105-11.


Histologic Findings are Not Specific to CD

- IELS:*
- NSAIDS
- H. pylori
- SIBO
- Gastroenteritis
- IBD




Kakar S. AJG 2003. Mahadeva S. J Clin Path 2002. Hammer STG 2010.Shmidt E. GIE 2014.Aziz I. APT 2010.

Proposed Algorithm



Late Histologic Mimickers


Villous atrophy, partial/total (Marsh 3+)





Autoimmune Enteropathy





Patey-Mariuad DE, et al. Mod Pathol 2009;22:95-102. Akram S, et al. CGH 2007;5:1282-90.

Autoimmune Enteropathy


- Increased recognition
 - Equal M:F
 - Age mean 44-55 years
 - Delay in dx median 1.5 years
- Refractory diarrhea and nutritional issues
- No response to diets



Anti-goblet cell antibodies are common and non-specific. 30-40% prevalence in population of healthy + disease.


> Akram S, et al. CGH 2007;5:1282-90. Sharma A, et al. CGH 2018;16:887-83.

Autoimmune Enteropathy vs Others




<u>Autoimmune</u>

- No goblet cells; no Paneth cells
- Surface IELs less prominent
- Lymphoplasmacytic infiltrate



Other Enteropathies

- Goblet and Paneth cells present
- Surface IELs more prominent






Collagenous Sprue


- Clinical/histologic features of CD
 - Diarrhea, malabsorption

- Thick type 1 collagen
 - >10-20 um (reports of 260 um!)
 - Normal collagen < 5 microns
 - Half of a lymphocyte



Gastroenterology 2016;150:S307-8; BMJ Open Gastroenterol 2016; JGH 2017;32:120-7.


15 Year History of Collagenous Sprue (CS)



B Al-Bawardy, et al.Gastroenterology, 2016;150:S307-8.,

Management of Collagenous Sprue (CS)

- Review medications
 - Stop offenders
- Initiate gluten-free diet
 - If HLA permissive
- Immunosuppression
 - Budesonide, prednisone, AZA, infliximab, others



Review the meds!!! Gastroenterology 2016;150:S307-8;

BMJ Open Gastroenterol 2016; JGH 2017;32:120-7.




ARB-Induced Enteropathy

Systematic review: 82 case reports/series + 5 comparative studies

Patients (#)	248	
Type of ARB used	Olmesartan (223; 94%) Telmisartan (5; 2.0%) Irbesartan (4; 1.6%) Valsartan (3; 1.2%) Losartan (2; 0.8%) Eprosartan (1; 0.4%)	Other meds causing enteropathy: • Checkpoint inhibitors • Mycophenylate mofetil • Methotrexate
Age range(years)	45-89	
Range of time on drug	2 weeks – 13 years mean/n	nedian 3 years other studies)
HLA DQ2 or 8 positivity	71.4% (checked in 59% of patients)	
Negative celiac serology	98.8% (checked in 68% of patients)	
Failure of response to GFD	97.7%	
Complete symptom remission	97.4%	

Kamal A, et al. Gastroenterol Rep 2019;7:162-7. Gentile NM. Mayo Clin Proc 2013; Ziegler TR. Gastroenterology 2003.

Drug-Induced Enteropathy Management



U.S. Food and Drug Administration Search FDA < back to Drug Safety and Availability</td>

FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil

- Consider in the patient with:
 - Serologically-negative enteropathy
 - Collagenous deposition a clue
- Olmesartan started months to years earlier, leading to a delay in diagnosis
- Treatment:
 - Stop the medication if able
 - For immunosuppression, reduce dose if able



Combined Variable Immunodeficiency (CVID)

Impaired B cell differentiation, abnormal Ig production

Any age (most 20-45 at dx), M:F equal


+/-Respiratory and GI infections; delayed dx

Other features: autoimmunity, liver, lymphoma

CVID Criteria:

- IgG 2 SD below normal AND
- One other low Ig level (IgA or IgM) AND
- Failure to mount vaccine reaction
- Absence of other immunodeficiency

Combined Variable Immunodeficiency (CVID)





Histologic clues:

- Reduced plasma cells
 - 30% w/normal #
- IELs, villous atrophy
- Apoptosis, neutrophils
- "Empty" lamina propria

*Daniels, et al. Am J Surg Pathol 2007;31:1800-12.

People can have <u>CVID and celiac disease</u>! Hard to diagnosis – serologies negative!






Cornerstone of CVID Management:


Immune globulin replacement; Infection prevention




Tropical Sprue




Tropical Sprue





Don't forget <u>travel</u> <u>history</u> in the evaluation of serologicallynegative enteropathy!

Proposed Algorithm



Take-Home Points

All enteropathy is not celiac disease, even though it is most common Look for other clinical, laboratory or histologic clues in the case of a serologically-negative enteropathy, and include careful med review and travel history



THANK YOU!!!

EMAIL: OXENTENKO.AMY@MAYO.EDU



